A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Medical associations sue U.S. health leaders over COVID-19 vaccine restrictions, citing concerns about public health, vaccine ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

Health ministry has issued statement highlighting that extensive studies by ICMR and AIIMS, New Delhi have established there ...

Six major medical groups, and a pregnant physician, are suing HHS Secretary Robert F. Kennedy Jr. over changes he made to ...

A shortened, all-oral drug regimen worked well for some patients with pre-extensively drug-resistant tuberculosis (pre-XDR TB ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage pioneer in host-mimetic nanomedicine, affirmed its preparedness to address the continued ...

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage innovator in broad-spectrum antivirals, announced near-finalization of its adaptive clin ...

Indian pharmaceutical industry leaders defend Covid-19 vaccines amid concerns, emphasizing safety, efficacy, and global ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...